Spyre Therapeutics, Inc. 8-K

What Happened
Spyre Therapeutics (SYRE) filed an 8‑K on April 13, 2026 to announce positive initial 12‑week induction topline data from Part A of its Phase 2 SKYLINE trial of SPY001 in moderate‑to‑severely active ulcerative colitis (UC). The company said SPY001 met the primary endpoint and showed clinically meaningful secondary endpoint rates; Spyre also closed recruitment for Part A and opened enrollment for Part B. Spyre hosted a conference call and webcast on April 13, 2026 at 8:00 a.m. ET to discuss the results.

Key Details

• Primary endpoint: change in Robarts Histopathology Index (RHI) from baseline = -9.2 points (p < 0.0001) at Week 12.
• Clinical outcomes: clinical remission rate 40%; endoscopic improvement rate 51%; change in Modified Mayo Score = -3.7.
• Safety (SPY001, n=43): 6 subjects (14%) had any treatment‑emergent AE; 1 severe AE (2%) — chest pain in a patient with prior cardiac disease, ruled out for MI and deemed not drug‑related; no drug‑related SAEs, no deaths.
• Trial status and timelines: Part A recruitment closed; Part B enrollment open with three monotherapy cohorts (SPY001, SPY002, SPY003) and three combination cohorts (SPY120, SPY130, SPY230) randomized vs shared placebo. Proof‑of‑concept induction data expected mid‑2026 for SPY002 and Q3 2026 for SPY003; Part B induction data expected in 2027.

Why It Matters
These topline results show SPY001 achieved a statistically significant improvement on a key histologic measure (RHI) and produced meaningful clinical and endoscopic responses in a Phase 2 induction setting, which may de‑risk the program if confirmed in larger cohorts. Progression to Part B with multiple monotherapy and combination cohorts expands Spyre’s clinical plan and sets multiple upcoming data readouts (mid‑2026 to 2027) that investors will watch. Safety was reported as consistent with the drug class in this small dataset, but the sample size is limited and additional data are needed to confirm efficacy and safety.